ERBB2 and breast carcinoma: Importantly, in another cohort (cohort D) of the JPCE trial, the safety of abemaciclib in combination with pembrolizumab and the aromatase inhibitor (AI) anastrozole was assessed in 26 patients with locally advanced or metastatic HR+/HER2- breast cancer (175).